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ISRecent successes of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV
infection have raised questions whether further placebo controlled trials of new HIV-
prevention technologies are ethically justifiable. A trial with active agent(s) in the
comparator group can be designed either as a superiority or non-inferiority trial. In a
non-inferiority trial the hypothesis tested is that the intervention is not inferior to, by a
predefined clinically relevant amount, or at least as effective as, the comparator. Non-
inferiority trials pose challenges in data interpretation.
Firstly it is possible to show equivalence of two non-effective interventions. If the active
comparator intervention is ineffective, the new intervention would be shown to be non-
inferior to this inactive intervention, while neither intervention is superior to placebo or
no intervention. The second challenge is that any effect that dilutes the true efficacy of
an intervention in a trial, such as non-adherence, loss to follow-up or protocol
violations, makes it easier for the two interventions to be declared equivalent. Non-
differential low adherence is unlikely to lead to the conclusion that an inferior
intervention is non-inferior. However, differential adherence between study arms,
which is more likely in non-blinded trials, is likely to bias the results and lead to
incorrect conclusions.
Investigators conducting non-inferiority trials will have to pay special attention to
supporting, measuring and maintaining high adherence. The goal in future non-
inferiority trials should be to maintain similar levels of high adherence in all study
arms, but at a minimum to reduce the likelihood of differential adherence across study
arms.  2012 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2012, 26:000–000Keywords: adherence, HIV prevention, non-inferiority trials, placebo controlled
trials, PrePIntroduction
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have sex with men [3]. While oral FTC-TDF (FEM-
PrEP) [4] and oral TDF (VOICE) [5] were not found to
be effective in heterosexual women, two trials showed in
July 2011 that oral TDF and FTC-TDF were found to
reduce HIV-transmission by 62% and 73% in serodis-
cordant couples (Partners PrEP) [6] and oral FTC-TDF
reduced HIV-transmission by 63% in heterosexual men
and women (TDF2) [7]. Furthermore, early antiretroviral
treatment initiation in the HIV-positive partner
(HPTN052) was shown to reduce HIV acquisition from
the positive partner in the HIV-negative partner in
serodiscordant couples by 96% [8]. These recent successes
have raised questions about the design of future HIV
prevention trials and whether further placebo controlled
trials of some new HIV-prevention technologies are
ethically justifiable [9].
As long as evidence about the efficacy of PrEP in
preventing HIV infection is ambiguous, future placebo
controlled trials are required. Currently estimates of the
efficacy of daily oral FTC-TDF in women ranges from no
efficacy [4] to 73% [6]. However, there is hope that
accumulating evidence may demonstrate a more con-
sistent estimate of PrEP effectiveness in the near future. In
this scenario, future placebo controlled trials may no
longer be possible.
One option for future trials which are designed to assess
the efficacy of new HIV prevention strategies is to include
these efficacious antiretroviral intervention(s) in both
intervention and control arms. In this case, the net effect is
to lower the overall HIV incidence rate in the trial
thereby making the trial larger and/or longer. This could
add substantially to the cost of the trial. In some instances,
it may not be safe, feasible or practical to implement a
known efficacious antiretroviral intervention simul-
taneously in a trial as it may interfere with the new
study intervention under investigation. For example, the
use of a vaginal ring containing an antiretroviral may be a
contra-indication for the simultaneous use with a gel
containing the same or a different antiretroviral. In such
cases, another option is to include efficacious antire-
troviral intervention(s) only in the comparator group.
A trial with active agent(s) in the comparator group can
be designed either as a superiority or non-inferiority trial.
In a superiority trial, the hypothesis tested is that the new
intervention under investigation is better, by a clinically
relevant amount, than the comparator, which can be
either standard of care, placebo or another active
intervention. This can be done either as a blinded or
open label trial. The new intervention needs to be even
more potent than an active comparator in order to show
superiority i.e. higher efficacy.
In a non-inferiority trial the hypothesis being tested is
that the intervention under investigation is not inferior to,pyright © Lippincott Williams & Wilkins. Unauthoby a predefined clinically relevant amount, or at least as
effective as, the comparator [10]. Non-inferiority trials
are used when the new intervention is assumed to have
some benefits (e.g. improved safety, low cost, etc) over the
comparator intervention, but has similar efficacy [11].
Non-inferiority trials, however, are not without chal-
lenges in data interpretation [12].
The first challenge is that any intervention can easily be
shown to be non-inferior to a non-effective comparator
intervention; whether or not either intervention is
superior to placebo or no intervention [10].
The assumption made when an active comparator is used
in a non-inferiority trial is that the efficacy found in
another trial also applies to the population and
environment in the current trial; an assumption that
cannot, in most instances be readily tested. How similar
do two populations need to be before findings in one
population can be used to determine the active
comparator in another population? For example, can
we assume that oral FTC–TDF will be 44% effective in a
population of heterosexual women, because it was found
to be 44% effective in a population of men who have sex
with men? [3] The validity of this assumption was
challenged by the findings of a trial testing FTC-TDF in a
population of heterosexual women (FEM-PrEP) where
no protection against HIV was shown [4], while 73%
effectiveness was found in men and women in
serodiscordant relationships (PartnersPrEP) [6].
Consider a hypothetical new PrEP trial testing coital use
of oral tenofovir against daily use of oral tenofovir which
concluded equivalence; i.e. concluded that coital use of
oral tenofovir is not inferior to daily oral tenofovir. If we
drew this conclusion in August 2011, before the recent
findings of the VOICE study [5], we would have
concluded that coital tenofovir is 62% effective, based on
the effectiveness of daily oral tenofovir in the Partners
PrEP trial [6]. If, however, we drew this conclusion 3
months later in October 2011, after the recent
announcement from the VOICE study, we could
conclude that coital tenofovir is not effective. Without
a clear and consistent protective efficacy estimate for daily
oral tenofovir, it is difficult to provide a meaningful
interpretation of a non-inferiority trial assessing coital use
of oral tenofovir.
The second challenge is that any effect that dilutes the
true efficacy of an intervention in a trial such as non-
adherence to the study regimen, considerable loss to
follow-up or protocol violations, makes it easier for the
two interventions to be declared equivalent. Non-
adherence is a particular concern in these settings because
it difficult to reliably measure adherence levels in both
arms of a PrEP trial. Drug level monitoring is only a
partial solution, since this can only be done in the active
arm. A placebo with a biological marker of adherencerized reproduction of this article is prohibited.
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likely to lead to the false conclusion that the test
intervention is non-inferior to the active comparator than
a well conducted trial [10].
The standard approach to dealing with this problem is to
base the primary analysis of a non-inferiority trial on the
per protocol population and not on the intent-to-treat
population, as is standard with a superiority trial. This is
because the intent-to-treat analysis is biased towards
equality in conditions where many participants did not
follow study procedures. One of the most important
criteria for inclusion in the per protocol analysis is
adherence to the study regimen. In the CAPRISA 004
[2], iPrEx [3], Partners PrEP [6] and FEM-PrEP trials [4],
self-reported adherence and adherence based on appli-
cator or pill count was high. In the iPrEx trial there was a
poor correlation between reported adherence and drug
levels detected. This casts doubts on both the adherence
during this trial and on the validity of self-report. If
adherence is not accurately measured, an analysis based on
adherence or on the per protocol population determined
by adherence may lead to incorrect conclusions. More
reliable measures of adherence such as drug concen-
trations in the active arm could go some way towards
increasing the likelihood of high adherers being included
in the active arm of the per protocol analysis. A biologicalCopyright © Lippincott Williams & Wilkins. Unaut
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The study continued until 500 infections were observed in both arms com
aincorrect decision made.adherence marker will be needed for the placebo arm for
a valid comparison.
The importance of adherence in non-inferiority trials
should not be underestimated. Sub-optimal adherence in
a trial with an active comparator has the net effect of
making the result ‘‘flatter’’ but does not lead to an
erroneous conclusion of non-inferiority, provided
adherence levels are similar in each of the study arms
(Table 1). The exception occurs when adherence is zero
or very close to zero in each of the treatment arms; in this
case non-inferiority is invariably declared.
Differential adherence in the study arms is much more
complex and, under a range of scenarios, can lead to
incorrect conclusions (Table 1). If the true effectiveness of
both interventions are the same, the intervention with
higher adherence is favored in a non-inferiority study. If
an inferior, but still efficacious, intervention had higher
adherence than the more effective comparator, a
conclusion of non-inferiority would be made.
Adherence to an intervention is an important determi-
nant of whether a prevention strategy would have a public
health benefit; therefore the adherence to an intervention
is an important aspect of the determination of its efficacy.
However, if adherence to the comparator is low; onehorized reproduction of this article is prohibited.
cy of the comparator and new intervention in combination with
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Effectiveness (95% CI) Conclusion about
new intervention
0 (19%; 16%) Equally effective
0 (19%; 16%) Equally effective
0 (19%; 16%) Equally effective
0 (19%; 16%) Equally effective
99 (140; 66) Inferior
34(60% 12%) No more effective than controla
15 (37; 4) No more effective than controla
0 (19%; 16%) Equally effectivea
33 (20%; 44%) Superior
12 (5%; 26%) At least as effective as control
5 (13%; 21) At least as effective as control
0 (19%; 16%) Equally effective
33 (58%; 11%) No more effective than control
13 (34%; 5%) No more effective than control
6 (26%; 11) No more effective than control
0 (19%; 16%) Equally effective a
33 (20%; 44%) Superiora
50 (79%; 25%) Inferiora
7 (27%; 11%) No more effective than control
6 (26; 11) No more effective than control
13 (4; 27) At least as effective as controla
7 (28; 10) No more effective than control
3 (23; 13) No more effective than control
18 (2; 31) At least as effective as controla
bined. Non-inferiority boundary of 20% used.
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placebo-like effect created by lack of adherence to the
intervention even though this comparator was intended
to be an active intervention.
Differential adherence is unlikely in a double blinded trial
of similar interventions; where neither the study
participants, nor the investigators are aware of study
assignment. However, differential adherence is much
more likely where the comparator and the new
intervention are substantially different and blinding is
less likely. More specifically, if one intervention is an oral
formulation and the other intervention is topical,
different patterns of use might be likely and adherence
might differ substantially. The same holds for different
dosing strategies; for example where once daily dosing is
compared to coitally dependent dosing. Differential
adherence is also likely when the interventions have
different side effect profiles. Although no evidence of
differential adherence was found in the CAPRISA 004
trial [2], differential adherence was reported in the iPrEx
trial in some of the early visits, with lower adherence in
the active arm [3], probably due to drug side effects.
Extreme caution should be used when non-inferiority
studies are planned comparing different dosing strategies,
which are likely to lead to different adherence levels. It
might not be possible to compare formulations that are
very different, such as oral, ring and gel formulations, as
they are likely to be used differentially.
The third challenge with non-inferiority trials is their
large size, much larger than superiority trials [12]. The
PrEP trials which have recently announced results were all
designed as superiority trials with sample sizes between
1000 and 5000 participants. The topical PrEP trial
targeted 92 HIV infections[2], while the oral PrEP trial
targeted 85 infections. In contrast, a non-inferiority trial
with 80% power to show an intervention not more than
20% inferior to the active comparator would require
about 500 HIV infections. A non-inferiority limit of 20%
is probably too large if the active comparator is only 40%
effective, but small enough if the active comparator is 60
to 70% effective.Conclusions
In future efficacy trials of new HIV prevention
interventions, non-inferiority designs may become one
of the standard approaches. These designs are harder to
interpret and care should be taken to ensure that
comparison treatments are well understood.
In these study designs, adherence is a critical factor as it
may lead to spurious results. Differential adherence in the
treatment arms could lead to incorrect findings about thepyright © Lippincott Williams & Wilkins. Unauthotrue effectiveness of the interventions. Investigators
conducting non-inferiority trials will, of necessity, have
to pay special attention to supporting, measuring and
maintaining high adherence. The effect of differential
adherence between study arms should be considered
when interpreting the results.
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